Drug Type Small molecule drug |
Synonyms ABDNAZ, 1-溴乙酰基-3,3-二硝基氮杂环丁烷, RRX 001 + [2] |
Target |
Mechanism CD47 inhibitors(Cluster of differentiation 47 inhibitors), MYC inhibitors(Myc proto-oncogene protein inhibitors), NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US) |
Molecular FormulaC5H6BrN3O5 |
InChIKeyJODKFOVZURLVTG-UHFFFAOYSA-N |
CAS Registry925206-65-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Small Cell Lung Cancer | Phase 3 | US | 24 Dec 2018 | |
Squamous cell carcinoma of the oral cavity | Phase 2 | US | 12 Jul 2018 | |
Squamous Cell Carcinoma of the Oropharynx | Phase 2 | US | 12 Jul 2018 | |
Stomatitis | Phase 2 | US | 12 Jul 2018 | |
Advanced Cholangiocarcinoma | Phase 2 | US | 16 Jul 2015 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 2 | US | 01 Jun 2015 | |
Neuroendocrine Tumors | Phase 2 | US | 01 Jun 2015 | |
Refractory Ovarian Carcinoma | Phase 2 | US | 01 Jun 2015 | |
Small Cell Carcinoma | Phase 2 | US | 01 Jun 2015 | |
Metastatic Colorectal Carcinoma | Phase 2 | US | 01 May 2014 |
Phase 2 | 4 | ktuswegyal(fjzsykacbl) = nivvpzzuqg xqgnfsyfsr (udxinsbhmw, hwfaxmdmlr - cewcvchqli) View more | - | 24 Apr 2024 | |||
Phase 2 | Solid tumor Third line | 40 | ympksakcij(zkoiioseun) = ktlsttxevq otsbklaxpz (xfyvdgpahb ) View more | Positive | 21 Feb 2023 | ||
Phase 2 | Colorectal Cancer Third line | 34 | ktwbtorckm(fhldmglxvs) = wxxeashive kwvgbvxwxi (gylsotfjyu ) View more | Positive | 24 Jan 2023 | ||
ktwbtorckm(fhldmglxvs) = vxihtczjfl kwvgbvxwxi (gylsotfjyu ) View more | |||||||
Phase 2 | 53 | vaxvblcovv(fypygdkdir) = RRx-001 were well tolerated with no associated serious adverse events wpmsnuqkhy (ucxkhnxwjq ) View more | Positive | 02 Jun 2022 | |||
Standard-of-care | |||||||
Phase 1/2 | 31 | Radiation Therapy+RRx-001 | qxpcvimvce(hvvjbctdru) = kwxctiyizf yttoctauwl (fnjfcuoegs ) View more | Positive | 01 Jul 2020 | ||
Phase 1 | 12 | pstsxlbvej(brtqkgbewe) = 2 events (leukopenia and anemia only related to irinotecan) nqobdfhxnn (dngivjalxo ) View more | Positive | 29 May 2020 | |||
NCT02518958 (ASCO2020) Manual | Phase 1 | 12 | tgbdaaeuca(xybqwutwsf) = pain on infusion (33.3%) qxeswgukpz (bqfmyuslwh ) View more | Positive | 29 May 2020 | ||
Phase 2 | 18 | lahsrxlcba(oqkddxecmn) = The main adverse event attributed to RRx-001 treatment, which involved once weekly peripheral or central infusion, was a painful infusion-related superficial phlebitis in 80% of patients. iiizysvqea (wzhtxbjapb ) View more | Positive | 25 May 2020 | |||
Phase 2 | 53 | tatafauojn(jdcankckqc) = ldnhbpxfwr snihesbmxh (vpkxebjebc ) | Positive | 25 May 2020 | |||
(Standard of care) | tatafauojn(jdcankckqc) = xfustluglw snihesbmxh (vpkxebjebc ) | ||||||
Phase 1 | Neoplasm Metastasis CD47 | tumor associated macrophages (TAMs) | 12 | qtsoxmcvtp(kmhrnmswtk) = 8.3% umhowaqykb (hyficlrzge ) View more | Positive | 01 Nov 2019 | ||
Nivolumab |